Abstract: Disclosed herein are antimicrobial compounds, compositions, pharmaceutical compositions, and the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

Abstract: The current disclosure is related to decreasing or inhibiting inflammation and/or an immune response as well the prevention and treatment of diseases including autoimmune and musculoskeletal diseases, and injuries, using an active fraction of or a molecule isolated from protein rich plasma. The current disclosure also includes a method of obtaining an active fraction of protein rich plasma.

Abstract: The present disclosure relates to a composition capable of promoting hair growth, including a pulchinenoside active component of pulchinenoside B4 or pulchinenoside B5. The experiment results are showed that the composition of the present disclosure can promote hair growth in a hair removal area of mice, improve its growth speed and increase the number of hair follicles, and has non-toxic side effects, low cost and rapid curative effect. The present disclosure also discloses a drug capable of promoting hair growth, including a pulchinenoside active component of pulchinenoside B4 or pulchinenoside B5. The present disclosure also discloses pulchinenoside B4 or pulchinenoside B5 as an active component in preparation of the composition or drug capable of promoting hair growth.

Abstract: The present disclosure provides a pharmaceutical composition for treating sepsis and use thereof, belonging to the technical field of chemical drugs. The present disclosure provides a three-component pharmaceutical composition including hydroxysafflower yellow A (HSYA), paeoniflorin, and albiflorin. The present disclosure further provides a seven-component pharmaceutical composition including HSYA, paeoniflorin, albiflorin, oxypaeoniflorin, senkyunolide I, salvianic acid A sodium (SAAS), and ferulic acid. In the present disclosure, it is verified at the cell level and the animal level that both two groups of the pharmaceutical compositions have an efficacy of effectively treating sepsis. Meanwhile, drug toxicity experiments show that the two groups of the pharmaceutical compositions both are safe. The pharmaceutical composition is an active ingredient of the Xuebijing Injection, which can be used for the clinical treatment of sepsis.

Abstract: The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more renal diseases in a non-human mammal, such as a carnivore, in particular a cat or a dog.

Abstract: Provided is a cocrystals of remdesivir (RDV) composed of a 1:1 molar ratio of RDV and benzoic acid derivative. The benzoic acid derivative can be salicylic acid (SA). The RDV-SA cocrystal are formed by either liquid-assisted grinding or spray-drying, followed by thermal annealing to facilitate cocrystal formation. The RDV-SA cocrystals can be formulated as inhalable dry powders and included in a medicament for use in treatments for influenza viral infections, such as COVID-19. The inhalable RDV-SA cocrystal dry powders is suitable for deep lung delivery, with good dissolution performance.

Abstract: The present invention relates to compositions, particularly compositions useful in maintaining and supporting healthy microflora in the female urogenital tract which could lead to inhibition of vaginal infections, as well as methods of treating and preventing vaginal infections. Compositions useful in supporting healthy microflora, disclosed herein, generally include a first therapeutic agent including ? methyl-D glucoside and a second therapeutic agent including a nitrogen containing compound at a therapeutic amount. In some embodiments, the nitrogen containing compound can be, for example, L-Cysteine, Cytidine, D-Asparagine, Pyrimidine, D-Alanine, D-Glucosamine HCL, and N-Acetyl-D-Glucosamine.

Abstract: Described herein are compounds, and pharmaceutically acceptable salts thereof, as well as methods of using those compounds to, among other things, treat severe acute respiratory syndrome.

Abstract: A pharmaceutical composition, including nicotinamide adenine dinucleotide (NAD) and a CD38 inhibitor in a weight ratio of 1-5:5-1, where the CD38 inhibitor is compound 78c. A pharmaceutical preparation including the pharmaceutical composition and an application of the pharmaceutical composition in the prevention and/or treatment of doxorubicin-induced cardiotoxicity are further provided.

Abstract: The invention relates to a synthetic sialoside presenting the formula (I): Neu5-Ac-?2-6-R1(R2)[GlcNAc?1-4]n-GlcNAc Formula wherein: -GlcNAc is N-acetylglucosamine; -GlcNAc?1-4 ia a N-acetylglucosamine unit linked with a ?1-4 link; -n is a superior or equal to 1; -R1 is a glycan structure comprising at least one galactose (Gal); and -R2 is chosen among the following groups: H, fucose linked with a ?1-3 link (Fuc?1-3) or a1-4 link (Fuc?1-4).

Abstract: The disclosure relates to a fiber blend for a health benefiting nutrition formulation, comprising: a resistant starch obtained from one or more sources selected from the group consisting of green banana resistant starch, maize or corn resistant starch, and potato resistant starch, the resistant starch having a resistant starch weight; an oat beta glucan having a beta glucan weight; and a maize or corn resistant dextrin having a resistant dextrin weight. The ratio of [the resistant starch weight]:[the beta glucan weight]:[the resistant dextrin weight]=1:0.15-4:0.15-4.

Abstract: The present disclosure provides compositions comprising one or more polymers capable of forming a hydrogel and methods for making and using the same. More specifically, the present disclosure provides compositions comprising one or more polymers capable of forming a hydrogel with prolonged mucosal retention, and methods for making and using the same.

Abstract: A lutetium salt compound for providing an antiviral effect against DNA and RNA viruses on infected cells, where the DNA and RNA viruses comprise Adenovirus, Poliovirus, Herpes Simplex Type 1, Herpes Simplex Type 2, Coronavirus, and Norovirus. Specifically, the lutetium salt compound includes lutetium borate, lutetium chloride, and lutetium nitrate.

Abstract: A formulation for an antiviral nasal composition effective in reducing viable pathogens and, more particularly, effective as preventive and adjuvant therapy for nasal infections or diseases caused by other pathogens.

Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.

Abstract: Provided herein are compositions and methods for the treatment of cancers using modified TILs, wherein the modified TILs include one or more immunomodulatory agents (e.g. cytokines) associated with their cell surface. The immunomodulatory agents associated with the TILs provide a localized immunostimulatory effect that can advantageously enhance TIL survival, proliferation and/or anti-tumor activity in a patient recipient. As such, the compositions and methods disclosed herein provide effective cancer therapies.

Abstract: The present disclosure provides anti-inflammatory extracellular vesicles (EVs) derived from ex vivo-expanded human suppressive immune cells. e.g., regulatory T cells (Tregs). Such EVs are useful in the treatment of diseases such as amyotrophic lateral sclerosis (AES). Alzheimer's disease, and other neurological diseases, as well as inflammatory and autoimmune diseases or dysfunctions.

Abstract: Provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and their use in directing immune responses to target cells. The compositions have uses that include treating hyperproliferative disorders such as cancer. The provided methods generally include the use of a CAR cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune response in vitro and in vivo. In some embodiments, the CAR cell comprises a genetic modification to reduce or eliminate the expression of a targeted antigenic determinant.

Abstract: The present invention provides a cell which comprises a first exogenous nucleic acid molecule encoding a Chimeric Antigen Receptor (CAR) and a second exogenous nucleic acid molecule encoding a transcription factor.

Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells comprising antigen recognizing receptors (e.g., chimeric antigen receptors (CARs) or T cell receptors (TCRs)), and expressing increased level of IL-18. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and resistant to immunosuppression and/or have enhanced immune-activating properties.

Abstract: Embodiments relate to a modified cell comprising a polynucleotide encoding an antigen binding molecule and a polynucleotide encoding an agent targeting one or more extracellular matrix (ECM) molecules. In embodiments, the polynucleotide encoding the agent comprises at least a nucleic acid encoding Cathepsin K (CK), a nucleic acid encoding Neutrophil Elastase (NE), or a nucleic acid encoding MMP7. In embodiments, the nucleic acid encoding NE comprises a nucleic acid encoding NE and a nucleic acid encoding a signaling domain of IL2. In embodiments, expression of the polynucleotide encoding the agent is regulated by hypoxia-inducible factor 1-alpha (HIF1?), nuclear factor of activated T-cells (NFAT), forkhead box P3 (FOXP3), or nuclear factor kappa B (NF-?B).

Abstract: NK cells and NK cell lines are modified to increase their cytotoxicity. proliferation. metabolic profile and persistence. wherein the cells and compositions thereof have a use in the treatment of cancer.

Abstract: Provided herein are nucleic acids, expression cassettes, modified lymphocytes and compositions comprising the same which include a sequence encoding a gene of Table 1. In some embodiments, the gene is LTBR. In certain embodiments, the cell is a T cell. In certain embodiments, the cell further comprises a CAR or engineered TCR. Methods of treatment using the provided compositions are also described.

Abstract: The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DOK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DOK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.

Abstract: B cell subsets, generation of B cell subsets and utilization of B cell subsets for treatment of Chronic Obstructive Pulmonary Disease (COPD). In one embodiment B cells possessing a B regulatory phenotype are generated in vivo by administrating of mesenchymal stem cells. In another embodiment B regulatory cells are utilized to treat COPD in an interleukin-35 dependent manner. In another embodiment B regulatory cells possess the marker CD5 and produce interleukin-10.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: Self-driving surface antigen-regulated promoter-therapeutic payload constructs containing antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the surface antigen-regulated promoter-therapeutic payload constructs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making self-driving surface antigen-regulated promoter-therapeutic payload constructs in T-cells are also disclosed.

Abstract: The invention discloses a method to co-culture patient-derived tumor organoids and the corresponding patient's tumor-infiltrating lymphocytes from a tumor sample.

Abstract: The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.

Abstract: The present disclosure provides an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. The present disclosure also provides an isolated immune cell which expresses a receptor, interleukin-7, and chemokine (C-C motif) ligand 19.

Abstract: The subject invention pertains to methods to treat neurological dysfunctions by replacing neurons, glia, vascular cells, or any combination thereof to repair the central nervous system and other tissues by administering umbilical cord blood (UCB), mononuclear cells (MNC), or red cell fraction (RCF) to a subject.

Abstract: Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject, comprising administering an effective dose of the platelet derivatives in a platelet derivative composition to the subject. Such effective dose in illustrative embodiments, includes multiple individual doses, or a continuous dose administered within a time period, for example a time period of less than 4 hours. In certain aspects herein the subject is a subject having Hermansky Pudlak Syndrome (HPS). The platelet derivatives can have numerous characteristics provided herein that make them well suited to restore hemostatic functions in the subject. In some embodiments, the platelet derivatives are from a pool of donors, and are HLA Class 1-characterized platelet derivatives (e.g., FDPDs), which in certain illustrative embodiments are HLA Class 1-matched FDPDs.

Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from equine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of equine cell therapies are provided.

Abstract: Described herein are implantable devices comprising cells genetically modified to express and secrete one or more immunomodulatory proteins. The devices and compositions thereof may be useful for treating immune-mediated inflammatory diseases.

Abstract: Compositions of matter, including cell populations and medicaments, are provided that are derived from canine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of canine cell therapies are provided.

Abstract: A composition and a method for treating diseases thereof are provided, wherein the composition comprises placental decidual mesenchymal stem cells, wherein the placental decidual mesenchymal stem cells overexpress decoy receptor 3 (DcR3) by stimulating with TNF-?, IFN-?, IL-6 or their combination thereof, and wherein the diseases including neurological diseases, eye diseases, and lung diseases.

Abstract: The present invention relates to a medicine composition for treatment of bone and joint diseases that has its ingredients (% by weight) as the dried extract of medicinal herbs: 40-75; tortoiseshell extract: 0.1-20; mixed bone extract: 0.1-20; deer antler extract: 0.1-20; salix alba extract: 5-25; nattokinase: 0.1-10; and Na-benzoate: 0-0.5, wherein the herbal medicine mixture comprises the ingredients of: Huang Bai (bark), Liquorice (root/rhizome), Hardy rubber tree (bark), Ox Knee (root), Fang Feng (root), Poria cocos wolf (fruit body), Chinese foxglove (rhizome), Sang Ji Sheng (whole tree), Gentian Root (root), Rhizoma Anemarrhena (rhizome), Peach blossom (blossom), Dried tangerine peel (peel), Chinese peony (root), Dangshen (root), Ginseng (root) Du Huo (root), Dongquai (root), Cinnamon (bough), Xi Xin (root, rhizome), Szechuan lovage (rhizome) and Dwarf umbrella tree (root).

Abstract: Corynebacterium strains for use in the prevention of a viral infection Certain enveloped RNA viruses preferably coro-naviruses primarily on the nasal mucosa, then the infection develops into a severe systemic disease. The infection and its course depend on individual susceptibility. The present inventors have found that SARS-COV-2 susceptibility is associated with differences in the overall nasal bacterial community structure. The invention utilizes among others the finding that Corynebacterium spp. has a major role in the prevention of infection and that the bacteria decrease the infection rate via multiple mechanisms. The invention is useful in the treatment and prevention of enveloped RNA virus infections in the upper respiratory tract.

Abstract: The present invention relates to, in part, compositions and methods for delivery of novel mixtures of bacterial strains for the decolonization and/or eradication of various pathogenic bacteria and, particularly, antibiotic-resistant bacteria (ARB).

Abstract: The current invention discloses the method of treating, preventing and/or ameliorating Inflammatory Bowel Disease in patients by administering a probiotic composition comprising Bacillus clausii. The current invention discloses a method for, prevention and/or treatment, and amelioration of symptoms of Inflammatory Bowel Disease by use of Bacillus clausii, which modulates the microbiome in the gastro-intestinal tract and decreases inflammation in the patients.

Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

Abstract: The present invention is directed to methods of administering a probiotic composition including Bacillus subtilis, Bacillus licheniformis, and Pediococcus acidilactici to dogs to decrease endotoxemia and improve the digestive process, and related methods.

Abstract: Provided are compositions methods of preventing, delaying or ameliorating atopic dermatitis in a breastfed infant having an increased risk of developing an atopic disease, the method comprising administering a composition comprising administering a Bifidobacterium to the breastfed infant.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: A matrix formulated with probiotics, which can be used to reduce the development of caries by inhibiting Streptococcus mutans and wherein the probiotics include: 3-5 g/100 mL pectin; 6-9 g/100 mL dextrose; 25-50 mg/100 mL citric acid; 2-4 mL/100 mL natural flavouring; and 4×10 12 CFU/mL of the microorganisms Streptococcus salivarius and Lactobacillus plantarum in active state. The matrix is administered to a patient to prevent dental caries.

Abstract: The present disclosure relates to an immune-enhancing composition comprising Lactobacillus rhamnosus LM1019 and starter strains. An immune-enhancing composition comprising Lactobacillus rhamnosus LM1019 and starter strains according to the present disclosure has an excellent immune-enhancing effect by increasing the amount of nitric oxide (NO) produced and improving the TNF-? secretion ability. Also, since the immune-enhancing composition contains the starter strain, it can be used to produce fermented milk. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Lactobacillus rhamnosus LM1019 strain was deposited with the international depositary authority: the Korean Culture Center of Microorganisms (KCCM) on Aug. 11, 2017, under the Accession Number: KCCM12308P.

Abstract: Provided herein are fumaric-containing compounds, compositions comprising the same and methods for using such compounds for increasing the capacity of an interferon-sensitive virus to infect, transduce, grow or replicate in a cell or spread within one or more tissues. Also provided are methods for increasing the capacity of an interferon-sensitive virus to produce a virus-encoded transgene from a cell, by administering the compounds and compositions.

Abstract: Provided herein in are armed Seneca Valley Viruses which have been altered to carry a therapeutic payload, i.e. to encode an agent for treating cancer. These armed Seneca Valley Viruses are oncolytic and express a cancer treating agent. Also provided herein are compositions and methods of using an armed Seneca Valley Virus to treat cancer in a subject.

Abstract: A method against coronavirus infection includes administering to a subject in need thereof a pharmaceutical composition containing a water-extracted product of Melastoma malabathricum root.